Ruveena Bhavani Rajaram

Ruveena Bhavani Rajaram

Auto-generated profile, based on publicly available information

Ruveena Bhavani Rajaram

Department of Medicine, University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
AKAshish Kumar
Ashish Kumar
AAAnil Arora
Anil Arora
ACAshok Choudhury
Ashok Choudhury
VAVinod Arora
Vinod Arora
MRMohamed Rela
Mohamed Rela
SSShiv Kumar Sarin
Shiv Kumar Sarin
INTRODUCTION: The prevalence of metabolic dysfunction–associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. METHODS: Patients with MAFLD-ACLF were recruited from the Asian Pacific Association for the Study of the Liver-ACLF Research Consortium (AARC registry). The diagnosis of MAFLD-ACLF was made when the treating unit had identified the etiology of chronic liver disease as MAFLD (or previous nomenclature such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or non-alcoholic steatohepatitis-cirrhosis). Patients with coexisting other etiologies of chronic liver disease (such as alcohol, hepatitis B virus, hepatitis C virus, etc.) were excluded. Data were randomly split into derivation (n = 258) and validation (n = 111) cohorts at a 70:30 ratio. The primary outcome was 90-day mortality. Only the baseline clinical, laboratory features and severity scores were considered. RESULTS: The derivation group had 258 patients; 60% were male, with a mean age of 53. Diabetes was noted in 27% and hypertension in 29%. The dominant precipitants included viral hepatitis (hepatitis A virus and hepatitis E virus, 32%), drug-induced injury (drug-induced liver injury, 29%), and sepsis (23%). Model for End-Stage Liver Disease-Sodium (MELD-Na) and AARC scores on admission averaged 32 ± 6 and 10.4 ± 1.9. At 90 days, 51% survived. Nonviral precipitant, diabetes, bilirubin, international normalized ratio, and encephalopathy were independent factors influencing mortality. Adding diabetes and precipitant to MELD-Na and AARC scores, the novel MAFLD-MELD-Na score (+12 for diabetes, +12 for nonviral precipitant), and MAFLD-AARC score (+5 for each) were formed. These outperformed the standard scores in both cohorts. DISCUSSION: Almost half of patients with MAFLD-ACLF die within 90 days. Diabetes and nonviral precipitants such as drug-induced liver injury and sepsis lead to adverse outcomes. The new MAFLD-MELD-Na and MAFLD-AARC scores provide reliable 90-day mortality predictions for patients with MAFLD-ACLF.

7 December 2017 in JGH Open
Verified
Journal Article
Open access
PDF file
RRRuveena Rajaram
Ruveena Rajaram
BSBaskar Subramani
Baskar Subramani
BABasri J J Abdullah
Basri J J Abdullah
SMSanjiv Mahadeva
Sanjiv Mahadeva
Mesenchymal stem cell (MSC) transplant may offer an alternative to liver transplantation in patients with end‐stage liver disease. However, its efficacy remains uncertain. MSC was performed on a 50‐year‐old male with decompensated (Child‐Turcotte‐Pugh grade C) alcoholic liver cirrhosis due to an absence of donors for adult‐deceased and living‐related liver transplantation. Autologous bone marrow‐derived MSCs were harvested from the patient and cultured using standard protocols. The MSCs were subsequently re‐administrated into the liver via hepatic intra‐arterial infusion on two separate occasions. After infusion, there was an improvement in biochemical parameters (serum total bilirubin, serum albumin), and a reduction of diuretic use for ascites for up to 8 weeks. However, all biochemical and clinical parameters deteriorated on long‐term follow‐up without any further infusions. The patient eventually succumbed to his disease. MSC transplantation may have a clinical benefit on adult patients with end‐stage liver cirrhosis, but this appears to be transitory.

25 October 2025 in Hepatology International
Verified
Journal Article
Closed access
PDF file
AKAshish Kumar
Ashish Kumar
AAAnil Arora
Anil Arora
PSPraveen Sharma
Praveen Sharma
RMRakhi Maiwall
Rakhi Maiwall
ACAshok Choudhury
Ashok Choudhury
APAPASL ACLF Research Consortium (AARC) for APASL ACLF working Party
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party

11 September 2021 in Joint Diseases and Related Surgery
Verified
Journal Article
Open access
RRRajat Ranjan
Rajat Ranjan
SRSanjiv Rampal
Sanjiv Rampal
AJAshish Jaiman
Ashish Jaiman
MTMehmet Ali Tokgoz
Mehmet Ali Tokgoz
JKJun Kit Koong
Jun Kit Koong
RRRuveena Rajaram
Ruveena Rajaram
Chronic liver disease (CLD) is the commonest ailment affecting the hepatobiliary system. Six significant pathologies related to CLD include hepatic osteodystrophy (HO), increased infection susceptibility, sarcopenia, osteonecrosis of the femoral head (OFH), increased risk of periprosthetic complications and fracture. Hepatic osteodystrophy, which comprises osteopenia, osteoporosis, and osteomalacia, refers to alterations in bone mineral metabolism found in patients with CLD. The HO prevalence ranges from 13 to 95%. Low complement levels, poor opsonization capacity, portosystemic shunting, decreased albumin levels, and impaired reticuloendothelial system make the cirrhotic patients more susceptible to developing infectious diseases. Septic arthritis, osteomyelitis, prosthetic joint infection, and cellulitis were common types of CLD-associated infectious conditions. The incidence of septic arthritis is 1.5 to 2-fold higher in patients with cirrhosis. Sarcopenia, also known as muscle wasting, is one of the frequently overlooked manifestations of CLD. Sarcopenia has been shown to be independent predictor of longer mechanical ventilation, hospital stay, and 12-month mortality of post-transplantation. Alcohol and steroid abuse commonly associated with CLD are the two most important contributory factors for non-traumatic osteonecrosis. However, many studies have identified cirrhosis alone to be an independent cause of atraumatic osteonecrosis. The risk of developing OFH in cirrhosis patients increases by 2.4 folds and the need for total hip arthroplasty increases by 10 folds. Liver disease has been associated with worse outcomes and higher costs after arthroplasty. Cirrhosis is a risk factor for arthroplasty complications and is associated with a prolonged hospital stay, higher costs, readmission rates, and increased mortality after arthroplasty. Greater physician awareness of risk factors associated with musculoskeletal complications of CLD patients would yield earlier interventions, lower healthcare costs, and better overall clinical outcomes for this group of patients.

6 August 2024 in Hepatology International
Verified
Journal Article
Closed access
PDF file
ACAshok Choudhury
Ashok Choudhury
RRRuveena Rajaram
Ruveena Rajaram
SSShiv Kumar Sarin
Shiv Kumar Sarin

1 January 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
RRRuveena B. Rajaram
Ruveena B. Rajaram
TJThevaraajan Jayaraman
Thevaraajan Jayaraman
BYBoon-Koon Yoong
Boon-Koon Yoong
PKPeng-Soon Koh
Peng-Soon Koh
PLPui San Loh
Pui San Loh
SMSanjiv Mahadeva
Sanjiv Mahadeva
Obesity and non-alcoholic fatty liver disease (NAFLD) are rampant in South East Asia. There is paucity of data exploring its' impact on donor suitability for living donor liver transplantation (LDLT). We aimed to describe and examine the factors related to non-utilization of potential donors in our LDLT programme. This is an analysis of prospectively collected data on potential donors for an adult LDLT programme, between January 2017 and December 2019. Fifty-five donors for 33 potential recipients were evaluated. The mean age was 31.6 ± 8.5 years, 52.7% were female and the ethnic divisions were: Chinese (50.9%), Indian (25.5%) and Malay (23.6%). The mean body mass index (BMI) among potential donors was 25.1 ± 4.0 kg/m2; 25.5% of donors had normal BMI, 23.6% were overweight and 50.9% were obese. Using the CAP modality of Fibroscan®, we identified the following grades of hepatic steatosis: 36.6% S0, 19.5% S1, 2.4% S2 and 41.5% S3. The non-utilization rate of our donors was 74.5% (41/55) and the main reasons were significant hepatic steatosis and/or obesity. Compared to suitable donors, unsuitable donors had significantly greater mean BMI, mean CAP scores, higher rates of dyslipidaemia and NAFLD. NAFLD and obesity represent major challenges to an emerging LDLT programme in Malaysia.